Related Experiment Videos

Human topoisomerase IIalpha and IIbeta interact with the C-terminal region of p53

I G Cowell1, A L Okorokov, S A Cutts

  • 1School of Biochemistry and Genetics, University of Newcastle, Newcastle upon Tyne, NE2 4HH, United Kingdom.

Experimental Cell Research
|February 10, 2000
PubMed

Insights

The p53 protein interacts with DNA topoisomerase II (topo II) alpha and beta in cells and in vitro. This interaction, crucial for cancer drug efficacy, is mediated by p53

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Biochemistry

Background:

  • The p53 protein is a key regulator of cell cycle arrest and apoptosis in response to DNA damage.
  • Certain anticancer drugs, like etoposide and doxorubicin, function by inhibiting DNA topoisomerase II (topo II), leading to DNA breaks and cell death.
  • Previous studies indicated an interaction between p53 and human topo IIbeta.

Purpose of the Study:

  • To investigate the interaction between p53 and both human topo IIalpha and topo IIbeta.
  • To determine the specific region of p53 involved in binding to DNA topo II.

Main Methods:

  • In vivo and in vitro assays were employed to study protein-protein interactions.
  • Analysis focused on the interaction between p53 and DNA topoisomerase IIalpha and IIbeta.

Main Results:

  • Both topo IIalpha and topo IIbeta were shown to interact with p53.
  • The interaction was confirmed to occur both in vivo and in vitro.
  • The C-terminal basic region of p53 (residues 364-393) was identified as essential and sufficient for binding to DNA topo II.

Conclusions:

  • p53 interacts with both isoforms of human DNA topoisomerase II.
  • The C-terminal region of p53 plays a critical role in mediating this interaction.
  • Understanding this interaction may provide insights into the mechanisms of action for topo II-targeting anticancer drugs.

Related Concept Videos